KLOW blend
Not FDA approvedMulti-peptide research blend
Also known as: KLOW peptide
Very thin human evidence
- Regulatory standing. Sold as a research chemical, not approved
- Anecdotal. Community reports, no controlled data
- No registered human trials. Nothing registered on ClinicalTrials.gov
- No sources. Nothing cited to verify
Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.
What it is
KLOW is a marketed combination of four separate peptides: GHK-Cu (a copper-binding tripeptide), BPC-157 (a synthetic fragment derived from a gastric protein), TB-500 (a synthetic fragment related to thymosin beta-4), and KPV (a tripeptide fragment of alpha-MSH). Each component has been studied, mostly in lab and animal models, for possible roles in tissue repair and inflammation signaling, and the blend is promoted on the idea that these effects might combine.
What the evidence shows
The KLOW blend is not FDA-approved, and no registered human trials or published studies of the combination itself were identified. Evidence for the individual components is largely preclinical, apart from some topical and cosmetic research on GHK-Cu, so claims about the blend's effects in humans are unsupported.
What is in this blend
A blend is scored on its own, but the evidence for each ingredient lives on its own profile. Mixing compounds adds unknowns that none of the individual studies cover.
Sources
Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.